Given this strong association with CDR and apparent generalizability to a community‐based cohort, AD signature cortical thickness could be a valuable measure to report in future clinical trials, as we seek to understand the impact of changes in brain structure in anti‐amyloid and anti‐tau therapies. Here, MAPT is linked to Alzheimer disease.